Delivery Order SPE2DR25D1100-SPE2DR26FCR0F
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) valued at $12,603.88 under a firm fixed-price contract. The award was made on December 3, 2025, with an ultimate completion date of December 4, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp will perform this order from its corporate office in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) valued at $14,581.87 under a firm fixed price contract type. This non-set-aside delivery order was awarded on October 22, 2025, with an ultimate completion date of October 23, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement across military...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) valued at $13,841.99 under a firm fixed-price contract type. The award was made on August 22, 2025, with an ultimate completion date of August 25, 2025, and represents a competitively awarded, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $4,684.70 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 4, 2025, with completion scheduled for June 5, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating open competitive award. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and this delivery...
- The Defense Logistics Agency awarded a delivery order valued at $6,840.95 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on November 24, 2025, with completion targeted for November 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its Corporate Office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) valued at $7,245.40 under a firm fixed-price contract. The award, issued on November 3, 2025, represents a non-competitive delivery order with an ultimate completion date of November 4, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for...
- The Defense Logistics Agency awarded a delivery order valued at $48,445.16 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) under a firm fixed price contract. The award, issued on November 14, 2025, with an ultimate completion date of November 17, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this delivery order from its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose) valued at $27,031.70 under a firm fixed-price contract type. The award was made on December 2, 2025, with an ultimate completion date of December 3, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 4, 2025, for the supply of RINVOQ ER 15 mg tablets in a quantity of 30 units. This is a firm fixed-price delivery order with a ceiling value of $37,623.45 and an ultimate completion date of December 5, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with a ceiling value of $11,447.60. This firm fixed-price, non-set-aside delivery order was awarded on November 18, 2025, with an ultimate completion date of November 19, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery order is...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FCR0FDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) valued at $4,735.95 under a firm fixed-price contract type. The award was made on November 24, 2025, with an ultimate completion date of November 25, 2025, and is classified as a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location. This delivery order represents a child contract under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle enables the pharmaceutical distributor to supply an extensive range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs and other federal healthcare systems worldwide. AmerisourceBergen Drug Corp's track record with the DLA demonstrates substantial capability in managing competitive pharmaceutical procurement across multiple therapeutic domains and delivery scales.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 11/23/25 |